1.16
4.92%
-0.06
After Hours:
1.13
-0.03
-2.59%
Alaunos Therapeutics Inc stock is currently priced at $1.16, with a 24-hour trading volume of 27,664.
It has seen a -4.92% decreased in the last 24 hours and a -6.45% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.20 pivot point. If it approaches the $1.07 support level, significant changes may occur.
Previous Close:
$1.22
Open:
$1.19
24h Volume:
27,664
Market Cap:
$18.57M
Revenue:
-
Net Income/Loss:
$-36.46M
P/E Ratio:
-7.25
EPS:
-0.16
Net Cash Flow:
$-30.20M
1W Performance:
-6.45%
1M Performance:
-6.45%
6M Performance:
+1,621%
1Y Performance:
+82.73%
Alaunos Therapeutics Inc Stock (TCRT) Company Profile
Name
Alaunos Therapeutics Inc
Sector
Industry
Phone
617 259 1970
Address
8030 El Rio Street, Houston
Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-04-22 | Resumed | Wells Fargo | Overweight |
Alaunos Therapeutics Inc Stock (TCRT) Latest News
Alaunos Therapeutics (NASDAQ:TCRT) investors are sitting on a loss of 78% if they invested three years ago - Yahoo Lifestyle UK
Yahoo Lifestyle UK
Ziopharm: Q1 Earnings Snapshot - Milford Mirror
Milford Mirror
Alaunos (TCRT) Stock Sinks As Market Gains: What You Should Know - Yahoo Lifestyle Australia
Yahoo Lifestyle Australia
Alaunos Therapeutics Announces Executive Financial Leadership Changes - TipRanks.com - TipRanks
TipRanks
Alaunos Therapeutics Announces Executive Financial Leadership Changes - TipRanks.com - TipRanks
TipRanks
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Alaunos Therapeutics Inc Stock (TCRT) Financials Data
Alaunos Therapeutics Inc (TCRT) Net Income 2024
TCRT net income (TTM) was -$36.46 million for the quarter ending September 30, 2023, a +9.68% increase year-over-year.
Alaunos Therapeutics Inc (TCRT) Cash Flow 2024
TCRT recorded a free cash flow (TTM) of -$30.20 million for the quarter ending September 30, 2023, a +19.87% increase year-over-year.
Alaunos Therapeutics Inc (TCRT) Earnings per Share 2024
TCRT earnings per share (TTM) was -$2.40 for the quarter ending September 30, 2023, a +15.79% growth year-over-year.
About Alaunos Therapeutics Inc
Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is based in Houston, Texas.
Cap:
|
Volume (24h):